Sees FY24 adjusted EBITDA up 50%. The company said, “The Company expects to make significant progress towards Adjusted EBITDA breakeven for full-year 2024 and anticipates Adjusted EBITDA to improve approximately 50% compared to full-year 2023.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TMCI:
- Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance
- Treace Medical Concepts, Inc. (TMCI) Q4 Earnings Cheat Sheet
- BTIG medical technology analyst to hold analyst/industry conference call
- Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
- Treace Medical announces interim three-year ALIGN3D study data
